Mission Statement, Vision, & Core Values of Bristol-Myers Squibb Company (BMY)

Are you curious about the driving force behind a leading biopharmaceutical company? What exactly are the core principles that guide its operations and strategic decisions? Let's delve into the mission, vision, and core values that define a prominent player in the pharmaceutical industry. Did you know that Bristol Myers Squibb's (BMS) total revenue for 2024 reached $48.3 billion, marking a 7% increase from the previous year?

Understanding these elements provides insight into how BMS aims to transform patients' lives through science, especially considering their substantial investment in research and development, which amounted to $11.159 billion in 2024. What are the specific values that underpin their commitment to patients, employees, and global communities? How does BMS translate its mission into tangible actions and innovations in the biopharmaceutical field?

Bristol-Myers Squibb Company (BMY) An Overview of

Bristol-Myers Squibb (BMY) has a long history, beginning in 1887 with the establishment of the Squibb Corporation. It officially became Bristol-Myers Squibb in 1989 through a merger. The company discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. Key therapeutic areas for BMY include oncology, hematology, immunology, and cardiovascular diseases.

As of April 2025, Bristol-Myers Squibb continues to be a major player in the pharmaceutical industry. The company's diverse portfolio includes well-known drugs and therapies that address a wide range of medical needs. BMY focuses on innovative research and development to bring new treatments to market. You can find more about the company's investor profile here: Exploring Bristol-Myers Squibb Company (BMY) Investor Profile: Who’s Buying and Why?

Bristol-Myers Squibb's financial performance in 2024 showed substantial revenue, driven significantly by key products. Recent financial reports highlight the company's success in various markets and the impact of its strategic initiatives. For example, in the fourth quarter of 2024, Bristol-Myers Squibb reported revenue of $11.2 billion. For the full year 2024, the company's revenue reached $46 billion. This growth was supported by strong sales from key products such as:

• Eliquis: A leading anticoagulant, with sales reaching $12.9 billion in 2024.
• Opdivo: An immunotherapy drug, contributing $9.1 billion in sales.
• Revlimid: Despite generic competition, it still generated $6.4 billion in revenue.

Bristol-Myers Squibb stands as a leader in the pharmaceutical industry due to its commitment to innovation, strategic market positioning, and robust financial performance. The company's focus on key therapeutic areas and its ability to develop and market successful drugs have solidified its position. To understand the factors behind Bristol-Myers Squibb's continued success, delve deeper into its mission, vision, and core values.

Bristol-Myers Squibb Company (BMY) Mission Statement

The mission statement of Bristol-Myers Squibb is 'To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.' This statement encapsulates the company's focus on innovation, patient-centricity, and commitment to addressing significant health challenges.

Bristol-Myers Squibb's mission statement is significant because it directly influences the company’s strategic goals, research and development efforts, and overall approach to the pharmaceutical industry. It acts as a guiding principle for decision-making at all levels of the organization, ensuring that the company’s activities are aligned with its core purpose of improving patient outcomes.

Here's an in-depth analysis of the core components of Bristol-Myers Squibb's mission statement:

Discover, Develop, and Deliver

This component highlights the company's integrated approach to creating new medicines, covering the entire process from initial research to making the drugs available to patients.

• Discover: This refers to the initial research and identification of potential drug candidates. In 2024, Bristol-Myers Squibb invested $9.5 billion in research and development, demonstrating its commitment to discovering new treatments.
• Develop: This involves the clinical trials and regulatory processes required to bring a drug from the lab to the market. The development phase is rigorous, ensuring the safety and efficacy of new medicines.
• Deliver: This focuses on manufacturing, distribution, and ensuring that the medicines reach the patients who need them. Bristol-Myers Squibb reported $46.38 billion in revenue for the 2024 fiscal year, reflecting its ability to deliver medicines on a global scale.

Innovative Medicines

This emphasizes the company's commitment to creating new and improved treatments. Innovation is central to Bristol-Myers Squibb's strategy, driving its research into novel therapies and approaches to address unmet medical needs.

• In 2024, Bristol-Myers Squibb's pipeline included several potential blockbuster drugs in oncology, immunology, and cardiovascular disease areas.
• For instance, the company is actively involved in developing cell therapies and immunotherapies, which represent cutting-edge approaches to treating cancer.

Help Patients Prevail Over Serious Diseases

This part of the mission statement underscores the company's focus on patient outcomes. It reflects a commitment to developing treatments that not only manage symptoms but also improve the overall quality of life for individuals facing severe health challenges.

• Bristol-Myers Squibb's patient-centric approach is evident in its patient support programs, which provide resources and assistance to individuals undergoing treatment.
• The company also collaborates with patient advocacy groups to better understand the needs of patients and ensure that their voices are heard.
• In 2024, Bristol-Myers Squibb allocated significant resources to patient assistance programs, helping to ensure that more patients have access to its medicines.

Bristol-Myers Squibb's dedication to delivering high-quality products and services is supported by its significant investment in research and development. The company allocated $9.5 billion to R&D in 2024, which is a substantial portion of its revenue, underscoring its focus on innovation. This investment translates into a robust pipeline of potential new medicines and therapies.

Furthermore, Bristol-Myers Squibb adheres to stringent quality control standards in its manufacturing processes to ensure the safety and efficacy of its products. The company’s facilities undergo regular inspections by regulatory agencies, and it continuously works to improve its processes and maintain the highest standards of quality. This commitment to quality is also reflected in its supply chain management, ensuring that medicines are delivered reliably and efficiently to patients around the world.

Bristol-Myers Squibb Company (BMY) Vision Statement

Bristol-Myers Squibb (BMS) aims to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. This vision is supported by core values focused on innovation, integrity, urgency, inclusion, and accountability. As of April 2025, the company continues to pursue this vision, adapting to the evolving healthcare landscape and focusing on key therapeutic areas.

The vision is reflected in the company’s strategic priorities and operational execution. Here's a detailed look at how BMS articulates and enacts its vision through various facets of its operations:

Focus on Innovative Medicines

BMS commits significant resources to research and development to discover and develop new medicines. In 2024, Bristol Myers Squibb invested $9.5 billion in Research and Development. This investment is aimed at advancing its pipeline of potential new therapies. The company focuses on several therapeutic areas:

• Oncology: Developing treatments for various types of cancer.
• Hematology: Addressing blood disorders with innovative therapies.
• Immunology: Creating solutions for immune-related diseases.
• Cardiovascular: Improving outcomes for patients with heart conditions.

For example, in oncology, BMS has been developing therapies that leverage the body's immune system to fight cancer, such as immune checkpoint inhibitors. These efforts align with their vision of helping patients overcome serious diseases by providing access to cutting-edge treatments.

Patient-Centric Approach

A core component of BMS’s vision is its commitment to patients. This patient-centric approach is evident in how the company designs clinical trials, engages with patient advocacy groups, and works to improve access to its medicines. The company aims to understand the patient experience and integrate those insights into its drug development and commercialization processes.

In 2024, BMS reported revenues of $46 billion, reflecting the impact of its diverse portfolio of medicines in addressing serious diseases. This financial performance enables the company to reinvest in R&D and patient support programs, reinforcing its commitment to its vision.

Global Health Impact

BMS extends its vision globally by addressing unmet medical needs in various regions. The company participates in global health initiatives and collaborates with international organizations to improve healthcare outcomes in underserved populations. This global perspective ensures that the company’s medicines and resources benefit patients worldwide.

BMS’s global initiatives also include efforts to strengthen healthcare infrastructure and train healthcare professionals in developing countries. By expanding its reach and impact, BMS aims to make a significant difference in the lives of patients, regardless of their location or socioeconomic status.

Commitment to Core Values

BMS’s vision is reinforced by its core values, which guide the company’s actions and decisions:

• Innovation: Continuously seeking new and better ways to address medical challenges.
• Integrity: Upholding the highest ethical standards in all its activities.
• Urgency: Acting quickly to deliver medicines to patients who need them.
• Inclusion: Embracing diversity and ensuring that everyone has the opportunity to contribute.
• Accountability: Taking responsibility for its actions and outcomes.

These values are integrated into the company’s culture and operations, shaping how employees conduct their work and interact with stakeholders. By adhering to these principles, BMS aims to build trust and credibility with patients, healthcare providers, and the broader community.

In conclusion, Bristol-Myers Squibb’s vision is to develop and deliver innovative medicines that help patients prevail over serious diseases. This vision is supported by a patient-centric approach, a commitment to global health, and core values that guide the company’s actions. As of April 2025, BMS continues to advance its vision through strategic investments, collaborative partnerships, and a relentless focus on improving patient outcomes. Exploring Bristol-Myers Squibb Company (BMY) Investor Profile: Who’s Buying and Why?

Bristol-Myers Squibb Company (BMY) Core Values of

At Company, a leading biopharmaceutical company, the mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. This mission is underpinned by a set of core values that guide the company's actions and decisions. These values reflect Company's commitment to making a meaningful difference in the lives of patients and contributing to a healthier future.

Passion

Company demonstrates its passion through a relentless pursuit of scientific innovation and a deep commitment to addressing unmet medical needs. This passion is evident in the company's significant investment in research and development. In 2024, Company invested $9.5 billion in research and development, reflecting its dedication to discovering and developing innovative medicines. This investment supports a broad pipeline of potential new medicines across a range of therapeutic areas, including oncology, immunology, and cardiovascular disease.

Examples of how Company demonstrates its commitment to passion:

• Investing $9.5 billion in R&D in 2024 to drive scientific innovation.
• Focusing on developing treatments for serious diseases like cancer, heart disease and immune disorders.
• Fostering a culture of collaboration and innovation among its scientists and researchers.

Innovation

Innovation is at the heart of Company's mission to develop transformative medicines. The company fosters a culture of innovation by encouraging its employees to think creatively, challenge conventional wisdom, and explore new scientific frontiers. Company's commitment to innovation is exemplified by its development of cutting-edge therapies, such as cell therapies and immunotherapies, which have revolutionized the treatment of certain cancers. As of 2024, Company's pipeline included more than 50 potential new medicines in various stages of development.

Examples of Company's commitment to innovation:

• Developing innovative therapies like cell therapies and immunotherapies.
• Maintaining a pipeline of over 50 potential new medicines.
• Partnering with academic institutions and other companies to accelerate the discovery and development of new medicines.

Integrity

Integrity is a cornerstone of Company's operations, guiding its interactions with patients, healthcare professionals, and other stakeholders. The company is committed to conducting its business ethically and transparently, adhering to the highest standards of compliance and accountability. Company's commitment to integrity is reflected in its comprehensive ethics and compliance program, which provides guidance and training to employees on ethical decision-making. In 2024, Company conducted over 100,000 hours of ethics and compliance training for its employees.

Examples of Company's commitment to integrity:

• Conducting over 100,000 hours of ethics and compliance training for employees in 2024.
• Adhering to the highest standards of ethical conduct in all its business activities.
• Promoting transparency and accountability in its interactions with stakeholders.

Urgency

Company recognizes the importance of delivering medicines to patients as quickly and efficiently as possible. The company is committed to accelerating the development and approval of new therapies, streamlining its processes, and working collaboratively with regulatory agencies to bring innovative medicines to market in a timely manner. Company's commitment to urgency is demonstrated by its efforts to expedite the review and approval of its new medicines. In 2024, Company received priority review designations from regulatory agencies for several of its investigational therapies.

Examples of how Company demonstrates urgency:

• Seeking priority review designations from regulatory agencies to expedite the approval of new medicines.
• Streamlining its processes to accelerate the development and delivery of new therapies.
• Collaborating with healthcare professionals and patient advocacy groups to address unmet medical needs.

Inclusion

Company values diversity and inclusion, recognizing that a diverse workforce and an inclusive culture are essential to its success. The company is committed to creating a workplace where all employees feel valued, respected, and empowered to contribute their best. Company's commitment to inclusion is reflected in its diversity and inclusion programs, which aim to attract, develop, and retain a diverse workforce. In 2024, Company spent $25 million on diversity and inclusion initiatives.

Examples of Company's commitment to inclusion:

• Investing $25 million in diversity and inclusion initiatives in 2024.
• Implementing programs to promote diversity and inclusion in its workforce.
• Supporting employee resource groups that provide a sense of community and belonging for employees from diverse backgrounds.

To gain more insights into Company's financial performance and strategic positioning, explore this in-depth analysis: Breaking Down Bristol-Myers Squibb Company (BMY) Financial Health: Key Insights for Investors